Malignant melanoma has been shown to be susceptible to T cell-mediated immunity and,
therefore, is a candidate for vaccination approaches. Clinical trials using dendritic cells (DC)
loaded with peptides corresponding to tumor antigens are ongoing in several institutions,
and some promising results have already been published. However, every single peptide-
based vaccine can only be used in a patient with a given single HLA type, and this strategy
is not appropriate for patients with rare HLA types or with tumors without defined antigens. A …